Shah Hirak, Fraser Meg, Agdamag Arianne C, Maharaj Valmiki, Nzemenoh Bellony, Martin Cindy M, Alexy Tamas, Garry Daniel J
Lillehei Heart Institute and Cardiovascular Division, Department of Medicine, University of Minnesota, Minneapolis, MN 55455, USA.
Advanced Heart Failure Program, Mechanical Circulatory Support Service and Cardiac Transplant Program, University of Minnesota, Minneapolis, MN 55455, USA.
Life (Basel). 2021 Oct 9;11(10):1063. doi: 10.3390/life11101063.
Cardiac transplantation requires the careful allocation of a limited number of precious organs. Therefore, it is critical to select candidates that will receive the greatest anticipated medical benefit but will also serve as the best stewards of the organ. Individual transplant teams have established prerequisites pertaining to recreational drug, tobacco, alcohol, and controlled substance use in potential organ recipients and post-transplantation. Legalization of cannabis and implementation of its prescription-based use for the management of patients with chronic conditions have been increasing over the past years. Center requirements regarding abstinence from recreational and medical cannabis use vary due to rapidly changing state regulations, as well as the lack of clinical safety data in this population. This is evident by the results of the multicenter survey presented in this paper. Developing uniform guidelines around cannabis use will be imperative not only for providers but also for patients.
心脏移植需要谨慎分配数量有限的珍贵器官。因此,挑选那些预期能获得最大医疗益处且能成为器官最佳管理者的候选者至关重要。各个移植团队已经制定了有关潜在器官接受者以及移植后使用消遣性药物、烟草、酒精和管制药品的先决条件。在过去几年里,大麻合法化及其基于处方用于慢性病患者管理的情况不断增加。由于各州法规迅速变化,以及该人群缺乏临床安全数据,各中心对于禁止使用消遣性和医用大麻的要求各不相同。本文所呈现的多中心调查结果就证明了这一点。制定关于大麻使用的统一指导方针不仅对医疗服务提供者至关重要,对患者也同样重要。